<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144579">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01859585</url>
  </required_header>
  <id_info>
    <org_study_id>PSU-0001</org_study_id>
    <nct_id>NCT01859585</nct_id>
  </id_info>
  <brief_title>Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion</brief_title>
  <official_title>Comparing the Efficacy of Parecoxib and Ketorolac as Preemptive Analgesia in Patients Undergoing Posterior Lumbar Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Parecoxib and Ketorolac as a
      preemptive analgesia in patients undergoing lumbar spinal fusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, double-blinded randomized control trial. Randomly allocated patient
      undergoing posterior lumbar spinal fusion into 3 groups (n=32) to receive Parecoxib,
      Ketorolac and Placebo around 30 minutes prior to incised skin. Efficacy was assessed by
      visual analog scale score (0-10), total opioid consumption, complication and bleeding also
      recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>Postoperative time up to 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>recorded as Verbal Numerical Rating Scare 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total amount of opioid consumption postoperatively</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Amount of drain output and Other Adverse effect</measure>
    <time_frame>7 days postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Parecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parecoxib</intervention_name>
    <description>Parecoxib 40 mg intravenous</description>
    <arm_group_label>Parecoxib</arm_group_label>
    <other_name>Dynastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Ketorolac 30 mg intravenous</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Ketolac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing lumbar spinal fusion for one to three levels

          -  ASA class I or II

        Exclusion Criteria:

          -  History of allergy to Sulfa group

          -  History of allergy to OPOID or NSAIDs

          -  Contraindicate to NSAIDs use

          -  History of coagulopathy or platelet disfunction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koopong Siribumrungwong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic Department, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Prince of Songkla University</name>
      <address>
        <city>Hadyai</city>
        <state>Sonkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>KOOPONG SIRIBUMRUNGWONG, MD</investigator_full_name>
    <investigator_title>Comparing the efficacy of Parecoxib and Ketorolac as preemptive analgesia in patients undergoing posterior lumbar spinal fusion</investigator_title>
  </responsible_party>
  <keyword>preemptive analgesia</keyword>
  <keyword>lumbar fusion</keyword>
  <keyword>Parecoxib</keyword>
  <keyword>Ketorolac</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
